Thomas Ebeling
Chairman of the Executive Board @ ProSiebenSat.1 Media
Boston, United States
Thomas Ebeling is a seed investor at ProSiebenSat.1 Media in Boston focused on Database and Health Care. Thomas Ebeling a standing member of OIF’s MSAB. After earning a degree in psychology in Hamburg, Thomas, began his career with Reemtsma in 1987, where he served as the product manager responsible for the “West” brand, among other duties. In 1991, he switched to Pepsi-Cola Germany, where he served as a marketing manager. In 1993, he was appointedMarketing Director for the entire beverage portfolio. Starting in 1994, he was National Sales and Franchise Director for the retail and restaurant sales of Pepsi-Cola. In 1996, he was appointed General Manager of Pepsi-Cola Germany. In 1997, he switched to Novartis, where he served as General Manager of Novartis Nutrition for Germany and Austria. In 1998, Thomas Ebeling assumed worldwide leadership of the Novartis Nutrition Division. In this position, he headed the three business units Medical Nutrition, Health Nutrition and Consumer Retail Brands, where, among other duties, he was responsible for the leading U.S. baby food brand Gerber. In 1998, he was appointed to the Novartis Executive Committee. From 2000 to October 2007, he served as CEO of the global Novartis pharmaceuticals business. Under his leadership, the company’s revenues more than doubled from US$11 billion to US$22.6 billion. In October 2007, he was appointed CEO of the Novartis Consumer Health Division. Since March 2009, he is CEO of ProSiebenSat.1 Media SE. Since 2012 Thomas Ebeling has been member of the supervisory board of Bayer AG and since 2013 he has been member of the board of directors of Lonza AG.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Thomas Ebeling invests in
Stages Thomas Ebeling invests in
Countries Thomas Ebeling invests in
Investment Focus
Industry
- Database 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Data Center Automation 1 (50%)
- Information Technology 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ImmuneAGE Bio
|
ImmuneAGE Bio is an intriguing initiative focused on drug discovery for immune system rejuvenation. Developing therapies that can rejuvenate or enhance the immune system could have profound implications for healthcare, especially in aging populations or those with compromised immune function | $2M / Seed / Jul 11, 2024 | |
Elicit
|
Elicit is an artificial intelligence research assistant that uses language models to help users automate research workflows. This research assistant finds relevant papers without a perfect keyword match, summarizes takeaways from the papers, and extracts key information from the papers. | $9M / Seed / Sep 25, 2023 |
Co-Investors
1517 Fund
1 deal together
Basis Set Ventures
1 deal together
Emerging Longevity Ventures
1 deal together
Fifty Years
1 deal together
Healthspan Capital
1 deal together
Illusian Founder Office
1 deal together
About ProSiebenSat.1 Media
ProSiebenSat.1 Media SE is a German mass media company operating television, radio stations and print businesses. The ProSiebenSat.1 Group is one of the largest independent media corporations in Europe with a reported reach of 42 million household around Europe. The company operates 15 television stations across Germany, Austria and Switzerland.ProSiebenSat.1 Media SE was established in 2000, with its headquarters in Unterföhring, Germany.
ProSiebenSat.1 Media Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Philipp Meixner
Investment Director
|
|||
|
Thomas Ebeling
Chairman of the Executive Board
|
|||
Conrad Albert
Deputy-CEO, Group General Counsel
|
|||
Gerald Madlmayr
Performance Manager
|
|||
Maximilian Conze
CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Thomas Ebeling invest in?
Thomas Ebeling invests primarily in Database, Health Care and Biotechnology startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Thomas Ebeling last invest?
The most recent investment recorded for Thomas Ebeling closed in Jul 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
